[
  {
    "ts": null,
    "headline": "Zoetis Q3: Strong Osteoarthritis Pain Franchise",
    "summary": "Zoetis' strategic divestiture of non-core assets and strong market position in companion animal drugs support a robust growth outlook. See why ZTS stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=73518badcef5e5d8c05b98fbb65fe3ca9ab49eb93d1d79234b8f47b7a7df3bc1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731280718,
      "headline": "Zoetis Q3: Strong Osteoarthritis Pain Franchise",
      "id": 131279163,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1629582255/image_1629582255.jpg?io=getty-c-w1536",
      "related": "ZTS",
      "source": "SeekingAlpha",
      "summary": "Zoetis' strategic divestiture of non-core assets and strong market position in companion animal drugs support a robust growth outlook. See why ZTS stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=73518badcef5e5d8c05b98fbb65fe3ca9ab49eb93d1d79234b8f47b7a7df3bc1"
    }
  }
]